Iwasaku Toshihiro, Okuhara Yoshitaka, Eguchi Akiyo, Ando Tomotaka, Naito Yoshiro, Masuyama Tohru, Hirotani Shinichi
Division of Cardiovascular Medicine, Department of Internal Medicine, Hyogo College of Medicine.
Int Heart J. 2017 Apr 6;58(2):232-237. doi: 10.1536/ihj.16-173. Epub 2017 Mar 21.
Although adaptive servo-ventilation (ASV) therapy has beneficial effects on chronic heart failure (CHF), a relatively large number of CHF patients cannot undergo ASV therapy due to general discomfort from the mask and/or positive airway pressure. The present study aimed to clarify baseline patient characteristics which are associated with the smooth introduction of ASV treatment in stable CHF inpatients.Thirty-two consecutive heart failure (HF) inpatients were enrolled (left ventricular ejection fraction (LVEF) < 45%, estimated glomerular filtration rate (eGFR) > 10 mL/minute/1.73m, and apnea-hypopnea index < 30/hour). After the patients were clinically stabilized on optimal therapy, they underwent portable polysomnography and echocardiography, and then received ASV therapy. The patients were divided into two groups: a smooth introduction group (n = 18) and non-smooth introduction group (n = 14). Smooth introduction of ASV treatment was defined as ASV usage for 4 hours and more on the first night. Univariate analysis showed that the smooth introduction group differed significantly from the non-smooth introduction group in age, hemoglobin level, eGFR, HF origin, LVEF, right ventricular (RV) diastolic dimension (RVDd), RV dp/dt, and RV fractional shortening. Multivariate analyses revealed that RVDd, eGFR, and LVEF were independently associated with smooth introduction. In addition, RVDd and eGFR seemed to be better diagnostic parameters for longer usage for ASV therapy according to the analysis of receiver operating characteristics curves.RV enlargement, eGFR, and LVEF are associated with the smooth introduction of ASV therapy in CHF inpatients.
尽管适应性伺服通气(ASV)疗法对慢性心力衰竭(CHF)有有益作用,但由于面罩带来的普遍不适和/或气道正压,相当多的CHF患者无法接受ASV疗法。本研究旨在阐明与稳定的CHF住院患者顺利引入ASV治疗相关的患者基线特征。连续纳入32例心力衰竭(HF)住院患者(左心室射血分数(LVEF)<45%,估计肾小球滤过率(eGFR)>10 mL/分钟/1.73m²,呼吸暂停低通气指数<30/小时)。在患者经最佳治疗临床稳定后,进行便携式多导睡眠图和超声心动图检查,然后接受ASV治疗。患者分为两组:顺利引入组(n = 18)和非顺利引入组(n = 14)。ASV治疗的顺利引入定义为第一晚使用ASV 4小时及以上。单因素分析显示,顺利引入组与非顺利引入组在年龄、血红蛋白水平、eGFR、HF病因、LVEF、右心室(RV)舒张末期内径(RVDd)、RV dp/dt和RV缩短分数方面存在显著差异。多因素分析显示,RVDd、eGFR和LVEF与顺利引入独立相关。此外,根据受试者工作特征曲线分析,RVDd和eGFR似乎是ASV治疗更长使用时间的更好诊断参数。RV扩大、eGFR和LVEF与CHF住院患者顺利引入ASV治疗相关。